196 related articles for article (PubMed ID: 37194527)
1. [Therapeutic Strategies for Hereditary Transthyretin Amyloidosis].
Ueda M
Brain Nerve; 2023 May; 75(5):539-541. PubMed ID: 37194527
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
3. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
[TBL] [Abstract][Full Text] [Related]
4. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T; Heo YA; Shirley M
Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
6. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Hayashi Y; Jono H
Biol Pharm Bull; 2018; 41(12):1737-1744. PubMed ID: 30504675
[TBL] [Abstract][Full Text] [Related]
9. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
10. TRANSTHYRETIN AMYLOIDOSIS THERAPIES: GUIDING THE FUTURE.
González-Duarte A
Rev Invest Clin; 2021; 73(5):310-315. PubMed ID: 34609369
[TBL] [Abstract][Full Text] [Related]
11. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
Maurer MS
Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
[TBL] [Abstract][Full Text] [Related]
12. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
[TBL] [Abstract][Full Text] [Related]
13. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
14. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
Warner AL
Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
[TBL] [Abstract][Full Text] [Related]
16. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
17. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
[TBL] [Abstract][Full Text] [Related]
18. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
Adams D; Koike H; Slama M; Coelho T
Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
[TBL] [Abstract][Full Text] [Related]
19. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
20. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]